Industry Experts

Paul Sauter completed his Ph.D. in organic chemistry at the Karlsruhe Institute of Technology specializing in organic synthesis. He then advanced bioorthogonal click chemistry for use in nuclear medicine and antibody-drug conjugates (ADCs) during his postdoctoral studies at the EMBL. As founding team member he has since led the chemistry R&D at VERAXA, focusing on optimizing bioconjugation and payload-linker chemistry. His efforts are dedicated to developing next-generation ADC platforms that enhance effectiveness while minimizing toxicity.